Ping Fan, Li Yu Xiu
Key Laboratory of Endocrinology of Ministry of Health,Department of Endocrinology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Oct 30;40(5):597-602. doi: 10.3881/j.issn.1000-503X.10524.
Nonalcoholic fatty liver disease(NAFLD)refers to hepatic steatosis without other known causes such as alcohol abuse or hepatic virus infection. NAFLD has become a chronic disease worldwide,and its prevalence is constantly growing. Hepatic insulin resistance caused by obesity results in the deposition of triglycerides in the liver,promoting the occurrence and development of NAFLD. Weight loss is the only safe and effective method for NAFLD. Lifestyle intervention plays a cornerstone role in treating NAFLD;however,most patients can not achieve and maintain the ideal body weight by lifestyle intervention alone. Glucagon-like peptide-1 receptor agonist and metabolic surgery are promising treatments for NAFLD.
非酒精性脂肪性肝病（NAFLD）是指无其他已知病因（如酗酒或肝病毒感染）的肝脂肪变性。NAFLD已成为全球范围内的一种慢性疾病，其患病率不断上升。肥胖引起的肝脏胰岛素抵抗导致肝脏中甘油三酯的沉积，促进了NAFLD的发生和发展。减肥是治疗NAFLD唯一安全有效的方法。生活方式干预在治疗NAFLD中起基石作用；然而，大多数患者仅通过生活方式干预无法达到并维持理想体重。胰高血糖素样肽-1受体激动剂和代谢手术是治疗NAFLD有前景的方法。
